Company Focus
AstraZeneca
Latest AstraZeneca News
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Related News
Insights
Company Spotlight
A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.
Latest News & Features of interest to AstraZeneca
Biotechnology
Ring Therapeutics, a biotech based in Massachusetts, USA, has announced strategic partnerships with Singapore’s Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI). 5 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Spanish drugmaker PharmaMar Group today said it has received a payment of $10 million from Janssen Products, a Johnson & Johnson (NYSE: JNJ) company, after reaching a commercial milestone for Yondelis (trabectedin). 5 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Pharmaceutical
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s presentation of its third-quarter financial results and latest outlook for 2024 as a whole. 5 November 2024
Biotechnology
French biotech Transgene today revealed it has entered into a license agreement with Germany-based contract development and manufacturing firm ProBioGen, fort he latter’s AGE1.CR.pIX suspension cell line. 5 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Pharmaceutical
Disc Medicine today announced a successful End of Phase 2 with the US Food and Drug Administration (FDA) supporting the regulatory path forward, including potential for accelerated approval, for bitopertin in erythropoietic protoporphyria (EPP). 4 November 2024
Latest In Brief for AstraZeneca
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Related Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
28 October 2024
26 October 2024
23 October 2024
22 October 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze